Alopecia areata is thought to be primarily driven by an immune attack at the hair follicle that leads to potentially reversible, non-scarring hair loss, but there’s still more to be discovered. Tune in to see what is currently thought to be the pathophysiology of alopecia areata, including the potential roles of the JAK and TEC kinase family signaling pathways.

© 2021 Pfizer Inc. All rights reserved. PP-RIL-USA-0023 October 2021

Now that vaccinated women have entered the screening population, we are seeing HPV 16 and 18 decreasing. These changes in HPV genotype prevalence may have a significant impact on the clinical management of cervical cancer, and an HPV test with extended genotyping may change the way we screen for cervical cancer as well. Joining Dr. Matt Birnholz to discuss the role of HPV extended genotyping in cervical cancer screening and the importance of identifying HPV 31 is Dr. Mark Stoler, Professor of Pathology and Clinical Gynecology at the University of Virginia Health System.

We are at a time when COVID-19, respiratory syncytial virus, and the flu all pose serious risks. Quick and accurate diagnoses are vital to determining the correct patient pathway and minimizing viral spread. But what diagnostic challenges do we face, and how can we overcome them? Joining Dr. John Russell to discuss these respiratory testing challenges and Cepheid’s 4-in-1 respiratory test is Dr. Greg Berry, Associate Director of the Center for Advanced Laboratory Medicine at the Columbia University Irving Medical Center in New York.

Many patients with multiple myeloma receive an immunomodulatory agent (IMiD) as part of their initial treatment, leading to a growing interest in what a patient’s next treatment should be if they don’t respond or become refractory to IMiDs. With the approval of an IMid-free regimen based on the CANDOR study results, these patients now have a treatment option.2 Drs. Jennifer Caudle and Joseph Mikhael discuss the regimen and the CANDOR study, including the key findings that came out of the study.

1. Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396:186-197.
2. KYPROLIS® (carfilzomib) prescribing information, Onyx Pharmaceuticals Inc., an Amgen Inc. subsidiary.

USA-171-81544 9/2021

Join Dr. Stuart Isaacson, a neurologist and movement disorder specialist, as he welcomes fellow neurologist and movement disorder specialist Dr. Salima Brillman and cardiologist Dr. Sean Beinart to discuss neurogenic orthostatic hypotension (nOH) causes, symptomatology, disease burden, and approaches to optimal management involving collaboration between neurology and cardiology specialists.

During their discussion, the following questions will be addressed:

1. What is nOH and how is it diagnosed?
2. What leads to symptoms of nOH?
3. What are some common and less common symptoms of nOH?
4. What is the impact of nOH symptoms on the patient and the caregiver?
5. How do we approach the management of nOH symptoms?
6. How can cardiologists and neurologists collaborate in managing patients with nOH?

For additional reference please review: Cutsforth-Gregory JK, Low PA. Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer. Neurol Ther. 2019 Dec;8(2):307-324.

© 2021 Lundbeck. All rights reserved. UBR-D-100900

Fabry disease is a progressive, genetic disorder that can cause multisystemic damage and reduce life expectancy when left undiagnosed and unmanaged, making the timely and appropriate management of Fabry disease essential. Recent clinical outcome data and real-world evidence led to the approval of Fabrazyme, a treatment option for Fabry disease. Joining Dr. Charles Turck to share that data is Dr. Joseph William Ray, an Associate Professor of Pediatrics and Director of Medical Genetics at the University of Texas Medical Branch.

For more information, please visit www.fabrazyme.com/hcp.

MAT-US-2107750-v1.0-08/2021

Even though biosimilars serve as a much-needed treatment option for patients in several fields of medicine, gastroenterologists have been reluctant to adopt them. Joining Dr. Jennifer Caudle to explore why this might be and the evolving role of biosimilars in anti-inflammatory care for GI patients is Dr. Stephen Hanauer, Professor of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

USA-CBU-81030

In order to reflect the evolving management of immune thrombocytopenia (ITP), the American Society of Hematology updated their clinical practice guidelines. Here to share some of the key recommendations for the management of adult and pediatric ITP is Dr. Keith McCrae, a board-certified hematologist and an author of the 2019 ASH Guidelines.

© 2021 Amgen Inc. All rights reserved. USA-531-80829 08/21

Throughout this 8-chapter program, you’ll hear from cardiologist Dr. Rachel Bond, cardiologist and vascular medicine specialist Dr. Geoff Barnes, and patient advocate Elizabeth about the increasing prevalence of peripheral artery disease (PAD) along with key strategies for diagnosing and managing patients with PAD.

©Janssen Pharmaceuticals, Inc. 2021 08/21 cp-230791v1

Neurogenic orthostatic hypotension (nOH) is a subset of orthostatic hypotension and is prevalent in patients with autonomic dysfunction.1,2 The cardinal symptoms of nOH include dizziness and lightheadedness,3 but frequently could include syncope, cognitive slowing, generalized weakness, coat-hanger (neck and shoulder) headache, fatigue, orthostatic dyspnea, blurred vision, and orthostatic angina.3 According to the Harris Poll conducted among nOH patients and their caregivers, the symptoms of nOH have a negative impact on activities of daily living. The symptoms are often minimized, poorly recognized/evaluated, or inadequately discussed and addressed.4

Patients with nOH may experience symptoms that can make daily tasks a challenge.1,5 The frequency and severity of symptomatic episodes can be unpredictable,6 and it is this unpredictability of events that contributes to a vicious cycle of nOH.1 In this cycle, fear of symptomatic events and falls may lead patients to reduce physical activity.1,5

References:

1. Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract. 2017;4(3):298-308.
2. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72.
3. Freeman R. Neurogenic orthostatic hypotension. N Engl J Med. 2008;358(6):615-624.
4. Claassen DO, Adler …